Saturday, December 27, 2014

Achieving Private Equity Returns, Minus the Drawbacks

What are the main problems that advisors try to solve in a client’s portfolio? 

To justify your own fees, performance that consistently outpaces the broader market indexes would be nice. However, you’re not willing to take on undue risk or volatility. Moreover, as an advisor you’re always focused on the cost of those investments, and an investment with high turnover goes against the long-term investing goal that most advisors have on behalf of their clients, not to mention the tax consequences of higher-frequency trading.

So perhaps you’re thinking that certain alternative investments would fit the bill. The problem with many alts, however, is that your clients may need to be part of the high-net-worth cohort. Burned by the 2008-2009 hyper-correlation and crash-and-burn of many private vehicles, you demand liquidity and transparency. Oh, you also can’t stomach the costs of 2-and-20 managers.

Enter Ben Warwick of QES Investments and a pairing of two investing vehicles — in ETF and mutual fund formats — that appears to go a long way toward meeting client needs for performance and diversification while assuaging advisors’ concerns about alternatives’ costs, transparency and liquidity.

Last month, an ETF was launched based on a QES private equity strategy on the London Stock Exchange, Source Nomura Modeled PERI ETF (PERI:LN). This past week, Hatteras Partners launched a mutual fund, Hatteras Private Equity Intelligence Fund (HPEIX). Both are built to deliver the benefits of private equity investing without the drawbacks of direct investing in listed or unlisted PE.

As CIO for the multi-office family office Sovereign Wealth Management, Warwick — a ThinkAdvisor and Investment Advisor contributor — and his team sought to use alternatives in performing asset allocation for larger portfolios. However, he found that there were “some negatives to what we were using,” the primary drawback being the “the delivery mechanism of the limited partnership.” Looking to deliver to his clients “access to risk premia that they wouldn’t have been able to access,” QES started by using futures, especially managed futures in portfolios as a strategic tilt away from the typical 60/40 portfolios.

Warwick realized that QES wanted to “build products that solve problems for advisors.” First up: the Aspen Managed Futures mutual fund (MFBTX), a low-cost index-based managed futures ’40 Act fund using both trend and countertrend strategies. He says the “low cost and the sensible structure of the index gave us some success with that product,” which has attracted $160 million in assets in just two years.

Around that time, however, “we started to see if we could make available the returns of private equity, specifically buyout funds.”

Why private equity? Simple, Warwick says. “Because the returns are better,” delivering 3% to 5% better returns than an unmanaged S&P 500 strategy. However, PE also requires that a HNW investor “tie up your money for a decade” more often than not.

So QES started conducting attribution analysis on PE returns to determine the source of those extra returns. While some observers would expect the returns come from “levered equity," Warwick said, "that doesn’t explain why private equity investments show a bigger upside with lower drawdowns.”

It turns out that individual managers’ alpha isn’t the primary driver, either, though he admits “there’s some of that.” Instead, what QES’ research found was that the “surprising driver” of PE returns is timing — “when you get in and when you get out” — and sector selection.

“Private equity managers are like hedge fund managers,” argues Warwick, in that they exhibit “herd behavior; if you see one or two deals in utilities,” for example, “you’ll see all these private equity managers going into utilities."

Since there’s a “momentum effect in capturing the money flows of PE, if you could capture that momentum effect and mirror the leverage, which changes with credit spreads, you could get close” to the returns of private equity funds. So QES needed to find the data on private equity funds to determine that momentum and timing.

Enter Preqin, which Warwick calls the “Morningstar of PE,” which has a “huge database” containing “30,000 transactions and 600 buyout funds.” Its data allowed QES to build portfolios that mimic the private equity buyout space.

Warwick says its PE index “went live a year ago, published on Bloomberg,” and true to QES’ research, “is providing good returns with less volatility.” The ETF, based on the Nomura QES Modeled Private Equity Returns Index, launched last month while the Hatteras mutual fund, HPEIX, launched last week.

How do the funds help advisors? “Lots of advisors” want to follow the endowment model, Warwick says, and allocate 30% to private equity, “but clients can’t afford that, so these funds allow you to cover the PE allocation.”

Moreover, the benefits of buying an index-based PE fund include ameliorating the “significant timing risk” of buying just one “vintage year” of PE. “If you buy into our funds, you get every vintage year in one trade; we look at the asset allocation of every vintage year in the database.”

Why not buy listed private equity, then? “Contrast our approach — trying to give returns from actual buyout funds — to listed PE, which buys the service providers of funds.” Listed PE, he says, is “very illiquid; ours (the ETF and mutual fund) are more liquid than the funds they’re wrapped into.”

The downside to PE index approach? “The big risk with our strategy is that we’re tied to how buyout funds do: if they don’t do well, then we won’t do well.”

However, Warwick says that “historically their downside participation in equity pullbacks is much more muted than the S&P 500,” partly because “we’ll always be a combination of long equity and cash.”

Why the cash? It’s all about the private equity need for ‘dry powder’ in the portfolio, i.e., the cash necessary to fund future buyouts. If the QES funds are mimicking the private equity funds, they’ll also mimic the amount of dry powder being held by PE funds. “Last year,” says Warwick, the average level of cash in the portfolio was 35%, but the portfolio yielded “S&P returns with 30% less volatility.”

What’s the role of the funds? “Some people are looking to use our fund as a smart beta, others put it in the alternatives bucket; pension plans see these as return drivers,” while “private banks see it as portfolio diversifiers.”

The cost? “The index has a 1% fee embedded in it,” plus trading costs.

The mutual fund’s final expense ratios are still to be determined by Hatteras, but it will provide, says Warwick, “far cheaper access to private equity.” Warwick himself says he’s a “significant investor in both the managed futures fund” and the private equity funds. “I’m a big believer in eating my own cooking,” he says.

---

Ben Warwick is a frequent contributor to Investment Advisor and writes the monthly Searching for Alpha index newsletter for ThinkAdvisor.com.

Ben also presented during a Nov. 12 ThinkAdvisor webinar on how to manage risk in a portfolio now.

5 Stocks Under $10 Triggering Breakouts

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

>>5 Stocks Insiders Love Right Now

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

>>5 Big Trades for a Market Top

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Mueller Water Products

Mueller Water Products (MWA) is a manufacturer and marketer of a broad range of water infrastructure, flow control and piping component system products for use in water distribution networks and water treatment facilities in North America. This stock closed up 2.3% to $7.83 in Thursday's trading session.

Thursday's Range: $7.61-$7.84

52-Week Range: $3.83-$8.13

Thursday's Volume: 1.04 million

Three-Month Average Volume: 1.37 million

>>5 Cash-Rich Stocks to Triple Your Gains

From a technical perspective, MWA trended modestly higher here right above its 50-day moving average of $7.43 with decent upside volume. This stock has been uptrending strong for the last two months and change, with shares moving higher from its low of $6.02 to its recent high of $8.13. During that move, shares of MWA have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of MWA within range of triggering a near-term breakout trade. That trade will hit if MWA manages to take out its 52-week high at $8.13 with high volume.

Traders should now look for long-biased trades in MWA as long as it's trending above its 50-day at $7.43 or above more key near-term support levels at $7.29 to $7.16 and then once it sustains a move or close above its 52-week high at $8.13 with volume that hits near or above 1.37 million shares. If that breakout hits soon, then MWA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $10 to $12.

Inteliquent

Inteliquent (IQNT) provides wholesale voice services for carriers and service providers. This stock closed up 2.2% to $8.25 in Thursday's trading session.

Thursday's Range: $7.92-$8.39

52-Week Range: $2.10-$11.30

Thursday's Volume: 608,000

Three-Month Average Volume: 704,432

>>4 Big Tech Stocks on Traders' Radars

From a technical perspective, IQNT trended modestly higher here right above its 50-day moving average of $7.24 with decent upside volume. This stock has been uptrending strong for the last month, with shares moving higher from its low of $5.73 to its intraday high of $8.39. During that move, shares of IQNT have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of IQNT within range of triggering a major breakout trade. That trade will hit if IQNT manages to take out some near-term overhead resistance levels at $8.54 to $9.07 with high volume.

Traders should now look for long-biased trades in IQNT as long as it's trending above its 50-day at $7.24 or above more near-term support at $7.01 and then once it sustains a move or close above those breakout levels with volume that hits near or above 704,432 shares. If that breakout hits soon, then IQNT will set up to re-test or possibly take out its next major overhead resistance levels at $10 to $12.

Cache

Cache (CACH) is a mall-based specialty retailer of lifestyle sportswear and dresses targeting style-conscious women. This stock closed up 7.1% to $4.82 in Thursday's trading session.

Thursday's Range: $4.48-$4.84

52-Week Range: $1.59-$4.99

Thursday's Volume: 117,000

Three-Month Average Volume: 71,035

>>4 Stocks in Breakout Territory on Big Volume

From a technical perspective, CACH ripped higher here right off its 50-day moving average of $4.52 with above-average volume. This move is quickly pushing shares of CACH within range of triggering a big breakout trade. That trade will hit if CACH manages to take out its 52-week high at $4.99 and some past resistance at $5 with high volume.

Traders should now look for long-biased trades in CACH as long as it's trending above some key near-term support at $4.40 and then once it sustains a move or close above those breakout levels with volume that hits near or above 71,035 shares. If that breakout triggers soon, then CACH will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $6 to $6.50.

Westell Technologies

Westell Technologies (WSTL) designs, manufactures and distributes telecommunications products to telephone companies and other telecommunications service providers. This stock closed up 6.9% to $3.09 in Thursday's trading session.

Thursday's Range: $2.89-$3.10

52-Week Range: $1.73-$3.15

Thursday's Volume: 153,000

Three-Month Average Volume: 190,163

>>3 Huge Stocks to Trade (or Not)

From a technical perspective, WSTL ripped higher here right above some near-term support at $2.82 with lighter-than-average volume. This stock has been uptrending strong for the last four months, with shares pushing higher from its low of $1.90 to its recent high of $3.15. During that uptrend, shares of WSTL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of WSTL within range of triggering a near-term breakout trade. That trade will hit if WSTL manages to take out Thursday's high of $3.10 and then its 52-week high at $3.15 with high volume.

Traders should now look for long-biased trades in WSTL as long as it's trending above some key near-term support levels at $2.82 or its 50-day at $2.71 and then once it sustains a move or close above those breakout levels with volume that hits near or above 190,163 shares. If that breakout triggers soon, then WSTL will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $3.60 to $4.

Dolan

Dolan (DM) is a provider of necessary business information and professional services to the legal, financial and real estate sectors in the U.S. This stock closed up 6.2% to $2.20 in Thursday's trading session.

Thursday's Range: $2.05-$2.23

52-Week Range: $1.37-$5.73

Thursday's Volume: 184,000

Three-Month Average Volume: 293,875

>>5 Rocket Stocks to Buy This Week

From a technical perspective, DM jumped higher here right above some near-term support at $2 and back above its 50-day moving average at $2.08 with lighter-than-average volume. This stock has been trending sideways and consolidating for the last month, with shares moving between $1.95 on the downside and $2.35 on the upside. Shares of DM are now starting to move within range of triggering a near-term breakout trade above the upper end of its recent sideways trading chart pattern. That breakout will hit if DM manages to take out some near-term overhead resistance levels at $2.25 to $2.35 with high volume.

Traders should now look for long-biased trades in DM as long as it's trending above its 50-day at $2.08 or above more near-term support at $2 to $1.95 and then once it sustains a move or close above those breakout levels with volume that hits near or above 293,875 shares. If that breakout triggers soon, then DM will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $2.60 to $2.84. Any high-volume move above those levels will then put $3 to $3.20 into range for shares of DM.

To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:



>>4 Stocks Rising on Unusual Volume



>>5 Hated Earnings Stocks You Should Love



>>5 Stocks Under $10 Set to Soar

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.


Thursday, December 25, 2014

3 Stocks to Get on Your Watchlist

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up on my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time came to choose which stock I'm buying or shorting next.

Today is Watchlist Wednesday, so I'm discussing three companies that have crossed my radar in the past week -- and at what point I may consider taking action on these calls with my own money. Keep in mind that these aren't concrete buy or sell recommendations, nor do I guarantee I'll take action on the companies being discussed. What I can promise is that you can follow my real-life transactions through my profile and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.

This week I thought it'd be fun to be a bit health-care-centric!

Merck (NYSE: MRK  )
Merck may be a gigantic, low-beta pharmaceutical company that you usually glance right over when scanning for income and value plays, but chances are you haven't kept up on two exciting developments that could help reignite its growth engine.

To begin with, the annual American Society of Clinical Oncology meeting in Chicago this past week shed light on a new class of immunotherapy drugs known as PD-1 inhibitors that suppress a protein suspected to be crucial to tumor growth. Heading into this meeting all eyes were on Bristol-Myers Squibb's (NYSE: BMY  ) Nivolumab -- and for good reason. In early-stage trials, the combination of Bristol's FDA-approved Yervoy and Nivolumab produced an overall response rate of 40% in advanced melanoma. The real surprise, though, came from Merck with its anti-PD-1 drug Lambrolizumab, which delivered an equally impressive overall response rate of 38% in advanced melanoma. There are still a lot of trials left to be run, but these ORRs are phenomenal. Having already received the designation of "breakthrough therapy" from the Food and Drug Administration, Lambrolizumab should be enough to get Merck investors excited.

However, Merck shareholders don't have to wait years before a potential blockbuster drug reaches the market. Investigational osteoporosis drug odanacatib is currently under safety and efficacy review by Merck with a new drug application expected to be filed by 2014. Odanacatib was so effective at reducing fracturing in late-stage trails that outside monitors stopped the trial early. With peak sales potential of $3 billion, according to Leerink Swann, Merck could be basking in a big sales boost sooner than later. To sum up, get Merck on your watchlist now!

Clovis Oncology (NASDAQ: CLVS  )
Welcome to fantasyland; population: Clovis shareholders! As my Foolish colleague and health care analyst David Williamson pointed out this week, shareholders enjoyed the best possible perk of biotech ownership Monday based on ASCO data -- a daily double. Clovis shares exploded higher as both its Rucaparib study of solid tumors, and CO-1686 for EGFR-mutant non-small-cell lung cancer, demonstrated strong early-stage results.

For Rucaparib, the effect was most notable in ovarian cancer, where there was an 89% clinical benefit to patients. In early studies of CO-1686, three of the four patients with the T790M resistance mutation demonstrated a partial response.

While certainly exciting, to believe that Clovis is worth anywhere near $2 billion is downright absurdity! This is a company whose most advanced drug, CO-101, failed to provide a statistical benefit in mid-stage metastatic pancreatic cancer trials in November and had to essentially start from scratch. Realistically, we're probably looking at two or three more years of losses and cash burn from Clovis before Rucaparib, assuming that all the stars align and the data continues to impress, has a shot of adding sales to Clovis' top line.

As of its most recent quarter, Clovis had nearly $130 million in cash, but I anticipate that it could burn through this entire amount over the next 18 months. This means that share dilution could be on the way unless Clovis finds a four-leaf clover in the form of an early-stage licensing partner. Following this week's run, I wouldn't be shocked to see a secondary offering filed later this week or early next week. Needless to say, this is prime short-sale material.

Regulus Therapeutics (NASDAQ: RGLS  )
Since presenting at the Deutsche Bank Healthcare Conference two weeks ago, shares of Regulus Therapeutics have been absolutely on fire. A mixture of ASCO and IPO fever have revived the love for newer issues, and having big name pharmaceutical companies gobbling up a majority of its IPO'd shares certainly helps its cause.

On paper, Regulus' microRNA technology and oligonucleotide database are intriguing and border on some very cool research possibilities. As an investment, however, where "cool" doesn't come into play, Regulus is a vampire company bound to suck the blood right out of investors if they dare invest at these levels.

The concern I have with Regulus is that its entire pipeline is purely based on preclinical studies with no interest in filing for an investigational new drug application until at least next year. This means that regardless of how many preclinical studies are under way, Regulus is going to be burning cash at an extraordinary rate for the foreseeable future.

Another head-scratcher is the company's preclinical hepatitis-C treatment known as miR-122. It's an intravenous treatment, partnered with GlaxoSmithKline, that's only now in preclinical trials. Perhaps someone should alert Regulus that it shouldn't waste its time as Gilead Sciences' (NASDAQ: GILD  ) oral Sofosbuvir cleaned up in all four of its late-stage hep-C trials with a favorable safety profile, and is currently under review by the FDA. With oral medications under development for years, what incentive do patients have to go back to an intravenous treatment?

It's questions like these that have me worried about Regulus' long-term viability as a publicly traded company. While I wouldn't write it off just yet, I also don't feel its recent run is anywhere near warranted and would suggest a possible short sale of the company.

Foolish roundup
Is my bullishness or bearishness misplaced? Share your thoughts in the comments section below, and consider following my cue by using these links to add these companies to your free, personalized watchlist to keep up on the latest news with each company:

Add Merck to My Watchlist. Add Clovis Oncology to My Watchlist. Add Regulus Therapeutics to My Watchlist.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.

Wednesday, December 24, 2014

Why NII Holdings Shares Soared Again

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Following a 25% jump on Wednesday, shares of NII Holdings (NASDAQ: NIHD  ) are soaring again today after the rumored sale has been made official.

So what: The company, which offers wireless service through its Nextel subsidiary, was reportedly exploring a sale of its Peru business to Chilean phone company Entel. NII officially announced the deal today, selling the division for $400 million. That's less than the $500 million figure that was originally speculated.

Now what: NII said the deal will contribute to its goal of focusing on its largest markets in Mexico and Brazil, adding that the proceeds will boost its liquidity position and ability to expand its next-generation networks in those regions. The company will also continue selling other assets to raise capital, with analysts expecting pending tower sales to be completed within the next few months. NII may be able to generate positive free cash flow by the end of next year.

Interested in more info on NII Holdings? Add it to your watchlist by clicking here.

It's incredible to think just how much of our digital and technological lives are almost entirely shaped and molded by just a handful of companies. Find out "Who Will Win the War Between the 5 Biggest Tech Stocks?" in The Motley Fool's latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.

Tuesday, December 23, 2014

IRS to auction remainder of Darryl Strawberry's Mets salary

mets darryl strawberry Strawberry took home four World Series titles over his 17-year Major League Baseball career. NEW YORK (CNNMoney) You can own a piece of baseball history, but it's nothing that can be put on a shelf.

The Internal Revenue Service is putting outfielder Darryl Strawberry's retirement annuity on the auction block next month.

The annuity, seized by the IRS because Strawberry owed back taxes, was part of a contract he signed in 1985, back when he was slugging home runs for the New York Mets.

The annuity will be worth about $1.3 million, to be paid out over nearly 19 years, when it goes up for sale on January 20, according to court documents.

The starting bid is $550,000.

The IRS filed a lien against Strawberry because he owes the IRS back taxes from 1989, 1990, 2003 and 2004. A court document from 2012 said he owed the IRS nearly $543,000.

The auction was authorized by a court, which will divide the money between the IRS and other parties.

The IRS will get to exchange two decades worth of monthly installments for an immediate lump sum that would settle Strawberry's outstanding tax debt.

Strawberry signed with the Mets in 1993 and over the course of his 17-year Major League Baseball career, took home four World Series titles. He was named an All-Star for eight consecutive seasons and had 335 career home runs. But he was plagued by a cocaine addiction and other troubles.

The auction is set to take place in Illinois, but bids will also be accepted by mail.